Patents by Inventor Nigel Paul King
Nigel Paul King has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180369258Abstract: A compound of formula (I) for use in the prevention or treatment of a bacterial infection wherein: PX is selected from the group consisting of (P1), (P2) and (P3).Type: ApplicationFiled: December 2, 2016Publication date: December 27, 2018Applicant: Auspherix LimitedInventors: Ian HOLMES, Alan NAYLOR, Dagmar ALBER, Jonathan Raymond POWELL, Meriel Ruth MAJOR, Gabriel NEGOITA-GIRAS, Daniel Rees ALLEN, Lucie Juliette GUETZOYAN, Nigel Paul KING, Nicholas Andrew CHAPMAN
-
Publication number: 20180360856Abstract: A compound of Formula (II): for use in the prevention or treatment of a bacterial infection.Type: ApplicationFiled: December 2, 2016Publication date: December 20, 2018Applicant: Auspherix LimitedInventors: Ian HOLMES, Alan NAYLOR, Dagmar ALBER, Jonathan Raymond POWELL, Meriel Ruth MAJOR, Gabriel NEGOITA-GIRAS, Daniel Rees ALLEN, Lucie Juliette GUETZOYAN, Nigel Paul KING
-
Patent number: 8877742Abstract: The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase enzymes.Type: GrantFiled: June 8, 2012Date of Patent: November 4, 2014Assignee: GlaxoSmithKline Intellectual Property LimitedInventors: Deborah W. Chen, Sarah Duncan, Nigel Paul King, Kiew Ching Lee, Sing Yeung Mak, Dean Andrew Rivers
-
Publication number: 20140155375Abstract: The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase enzymes.Type: ApplicationFiled: June 8, 2012Publication date: June 5, 2014Applicant: GlaxoSmithKline Interllectual Property LimitedInventors: Deborah W. Chen, Sarah Duncan, Nigel Paul King, Kiew Ching Lee, Sing Yeung Mak, Dean Andrew Rivers
-
Publication number: 20120283297Abstract: Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.Type: ApplicationFiled: December 16, 2010Publication date: November 8, 2012Applicant: GLAXO WELLCOME HOUSEInventors: James Bailey, Nigel Paul King, Xichen Lin, Feng Ren, Kheng-Chuan Tan, Sing Yeung Mak
-
Publication number: 20100179168Abstract: The present invention therefore provides compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders.Type: ApplicationFiled: April 13, 2007Publication date: July 15, 2010Inventors: Emma Louise Blaney, David Kenneth Dean, Alessandra Gaiba, Nigel Paul King, Jason Witherington
-
Patent number: 7713978Abstract: The present invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders.Type: GrantFiled: March 29, 2007Date of Patent: May 11, 2010Inventors: Nigel Paul King, Jason Witherington
-
Patent number: 7579366Abstract: The invention relates to epothilone analog represented by the formula I wherein (i) R2 is absent or oxygen; “a” can be either a single or double bond; “b” can be either absent or a single bond; and “c” can be either absent or a single bond, with the proviso that if R2 is oxygen then “b” and “c” are both a single bond and “a” is a single bond; if R2 is absent then “b” and “c” are absent and “a” is a double bond; and if “a” is a double bond, then R2, “b” and “c” are absent; R3 is a radical selected from the group consisting of hydrogen; lower alkyl; —CH?CH2; —C?CH; —CH2F; —CH2Cl; —CH2—OH; —CH2—O—(C1-C6-alkyl); and —CH2—S—(C1-C6-alkyl); R4 and R5 are independently selected from hydrogen, methyl or a protecting group; and R1 is as defined in the specification, or a salt of a compound of the formula I where a salt-forming group is present. A further aspect of the invention is related to the synthesis of epothilone E.Type: GrantFiled: March 11, 2003Date of Patent: August 25, 2009Assignee: The Scripps Research InstituteInventors: Kyriacos C. Nicolaou, Nigel Paul King, Maurice Raymond Verschoyle Finlay, Yun He, Frank Roschangar, Dionisios Vourloumis, Hans Vallberg, Antony Bigot
-
Patent number: 7517879Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.Type: GrantFiled: October 11, 2006Date of Patent: April 14, 2009Assignee: Glaxo Group LimitedInventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
-
Patent number: 7462614Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.Type: GrantFiled: March 29, 2004Date of Patent: December 9, 2008Assignee: Smithkline Beecham CorporationInventors: Mui Cheung, Nigel Paul King, Kevin Wayne Kuntz, Robert Anthony Mook, Jr., Mark Andrew Pobanz, James Michael Salovich, Brian John Wilson
-
Patent number: 7429587Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.Type: GrantFiled: October 11, 2006Date of Patent: September 30, 2008Assignee: Glaxo Group LimitedInventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
-
Patent number: 7381728Abstract: The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Re, Rf and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors. Pharmaceutical compositions comprising the compounds methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.Type: GrantFiled: July 26, 2005Date of Patent: June 3, 2008Assignee: Glaxo Group LimitedInventors: David Kenneth Dean, Alessandra Gaiba, Nigel Paul King, Andrew Kenneth Takle, Jason Witherington
-
Patent number: 7338960Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:Type: GrantFiled: June 18, 2003Date of Patent: March 4, 2008Assignee: SmithKline Beecham CorporationInventors: Richard Bell, Paul John Beswick, Romain Luc Marie Gosmini, Richard Martin Grimes, Christopher Charles Frederick Hamlett, Nigel Paul King, Vipulkumar Kantibhai Patel
-
Patent number: 7326785Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.Type: GrantFiled: October 11, 2006Date of Patent: February 5, 2008Assignee: Glaxo Group LimitedInventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
-
Patent number: 7282497Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.Type: GrantFiled: March 17, 2006Date of Patent: October 16, 2007Assignee: Glaxo Group LimitedInventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
-
Patent number: 7226929Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.Type: GrantFiled: March 17, 2006Date of Patent: June 5, 2007Assignee: SmithKline Beecham CorporationInventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
-
Patent number: 7186717Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.Type: GrantFiled: June 6, 2002Date of Patent: March 6, 2007Assignee: SmithKline Beecham CorporationInventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
-
Patent number: 7179835Abstract: The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.Type: GrantFiled: November 13, 2002Date of Patent: February 20, 2007Assignee: Glaxo Group LimitedInventors: Alan David Borthwick, Matthew Campbell, Chuen Chan, Henry Anderson Kelly, Nigel Paul King, Savvas Kleanthous, Andrew McMurtrie Mason, Stefan Senger, Paul William Smith, Nigel Stephen Watson, Robert John Young
-
Patent number: 7173137Abstract: Epothilone A, epothilone B, analogs of epothilone and libraries of epothilone analogs are synthesized. Epothilone A and B are known anticancers agents that derive their anticancer activity by the prevention of mitosis through the induction and stabilization of microtubulin assembly. The analogs of epothilone are novel. Several of the analogs are demonstrated to have a superior cytotoxic activity as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules.Type: GrantFiled: December 9, 2003Date of Patent: February 6, 2007Assignee: The Scripps Research InstituteInventors: Kyriacos C. Nicolaou, Yun He, Sacha Ninkovic, Joaquin Pastor, Frank Roschangar, Francisco Sarabia, Hans Vallberg, Dionisios Vourloumis, Nicolas Winssinger, Zhen Yang, Nigel Paul King, Maurice Raymond Verschoyle Finlay
-
Patent number: 7084139Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.Type: GrantFiled: June 6, 2002Date of Patent: August 1, 2006Assignee: SmithKline Beecham CorporationInventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young